Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9564637 | 0.91 | LMNA (0.68) | LMNARECQLALDH1A1CYP2D6L3MBTL1 | |
| SCHEMBL978754 | 0.88 | LMNA (0.55) | LMNARECQLALDH1A1CYP2D6L3MBTL1 | |
| SCHEMBL167129 | 0.81 | LMNA (0.52) | LMNARECQLALDH1A1CYP2D6L3MBTL1 | |
| SCHEMBL10476983 | 0.81 | LMNA (0.52) | LMNARECQLALDH1A1CYP2D6L3MBTL1 | |
| SCHEMBL6395059 | 0.81 | LMNA (0.52) | LMNARECQLALDH1A1CYP2D6L3MBTL1 | |
| SCHEMBL117951 | 0.81 | TSHR (0.62) | LMNARECQLCYP2D6L3MBTL1ADRB2 | |
| SCHEMBL6480727 | 0.81 | TSHR (0.62) | LMNARECQLCYP2D6L3MBTL1ADRB2 | |
| SCHEMBL4619478 | 0.81 | TSHR (0.62) | LMNARECQLCYP2D6L3MBTL1ADRB2 | |
| SCHEMBL27635301 | 0.80 | TSHR (0.41) | LMNARECQLALDH1A1MAPTTSHR | |
| SCHEMBL8187180 | 0.79 | LMNA (0.70) | LMNAALDH1A1CYP2D6L3MBTL1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945651-B1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | LUDWIG INST CANCER RES (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8334408-B2 | Analogs of alpha galactosylceramide and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120269857-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH | 2012-10-25 | — | — | US | disclosed |
| CN-101331146-B | Analogs of alpha galactosylceramide and uses thereof | LUDWIG INST CANCER RES | 2012-06-13 | — | — | CN | disclosed |
| US-8188313-B2 | Analogs of alpha galactosylceramide and uses thereof | THE UNIVERSITY OF BIRMINGHAM (GB) | 2012-05-29 | — | — | US | disclosed |
| US-20120034269-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | CERUNDOLO VINCENZO (GB) | 2012-02-09 | — | — | US | disclosed |
| US-8039670-B2 | Analogs of alpha galactosyceramide and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090239813-A1 | Analogs of Alpha Galactosyceramide and Uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2009-09-24 | — | — | US | disclosed |
| CN-101331146-A | Analogs of alpha galactosylceramide and uses thereof | LUDWIG INST CANCER RES (US) | 2008-12-24 | — | — | CN | disclosed |
| EP-1945651-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | The Ludwig Institute for Cancer Research (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007050668-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239813-A1 | Analogs of Alpha Galactosyceramide and Uses thereof | SGMS1, CERS2, SGMS2 | LMNA 1780/4885RECQL 2538/4885ALDH1A1 1362/4885 |
| US-20120034269-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | UGCG, CD69, GALC | LMNA 2398/4885RECQL 4802/4885ALDH1A1 2446/4885 |
| US-20120269857-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | UGCG, GALC, CD69 | LMNA 2195/4885RECQL 4800/4885ALDH1A1 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.